Close Menu

product launch

The assay should have a CE-IVD mark by November and will serve the Finnish molecular diagnostics firm's growing European client base.

The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.

 

The Bay Area firm has built on its enzymatic barcoding technology to deliver a high-throughput, synthetic long-read library preparation technique.

The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.

The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.

The service is the first of its kind in the UK and relies on the Illumina NovaSeq 6000 platform to deliver results.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.